BioInvent International AB (0H22)

Overview

BioInvent International AB (publ) is a pioneering force in the biotechnology field, focusing on the discovery, research, and development of immune-modulatory antibodies aimed at treating cancer. With its headquarters based in Lund, Sweden, BioInvent has established a commendable presence not only in its home country but also across Europe, the United States, and other international markets. Founded in 1996, the company operates at the clinical stage, concentrating its efforts on leveraging the power of the immune system to battle various forms of cancer through innovative therapies. Through its robust pipeline and strategic partnerships, BioInvent aspires to transform cancer treatment paradigms and improve patient outcomes worldwide.

Products and Services

BioInvent International AB (publ) boasts a diverse and promising product pipeline focused on immuno-oncology. Each drug candidate is at different stages of development, aimed at targeting various cancer types. Below are their key product offerings:

• BI-1206: A flagship product in development for the treatment of non-Hodgkin lymphoma and solid tumors. This antibody aims to address the mechanisms that cancer cells use to evade the immune system, providing a novel approach to cancer treatment.
• Tumor-Associated Myeloid Cells Modulators: These are therapies designed to target cells within the tumor microenvironment that suppress the immune response against cancer, potentially enhancing the efficacy of existing cancer treatments.
• Cancer-Associated Regulatory T Cells Modulators: Similar to the tumor-associated myeloid cells modulators, these therapies aim to inhibit the function of regulatory T cells that protect the tumor from the immune system, thereby enhancing the anti-tumor response.
• BT-001: Developed in collaboration with Transgene, BT-001 is a multi-functional oncolytic virus intended for the treatment of solid tumors. This innovative approach uses viruses to selectively infect and kill cancer cells, while also stimulating an immune response against the tumor.
• BI-1808 and BI-1910: These anti-TNFR2 antibodies are under development for the treatment of solid tumors and cutaneous T-cell lymphoma. By targeting TNFR2, these antibodies aim to overcome one of the mechanisms that tumors use to evade the immune response.

In addition to its core product lineup, BioInvent is engaged in strategic partnerships to expand and enhance its portfolio. Notably, the company has entered into collaborations with Transgene to co-develop BT-001 and with Merck to explore the potential synergy of BT-001 in combination with Keytruda, as well as in the investigation of BI-1808. These partnerships underscore BioInvent's commitment to advancing cancer treatment through innovation and collaboration.